Krueger 1999.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: DSM ‐ III ‐ R panic disorder with or without agoraphobia Method of diagnosis: SCID Axis I, Roche edition Age: for moclobemide, M = 35.0 (SD = 8.9); for clomipramine, M = 36.0 (SD = 9.5) Sex: for moclobemide, 41.8% males, 58.2 females; for clomipramine 39.7% males, 60.3% females Location: Norway, Sweden, the Netherlands; setting unclear Co‐morbidities: none, except of generalised anxiety disorders and social phobia of less than moderate severity Rescue medication: chloral hydrate as an occasional night time hypnotic
Interventions	Participants were randomly assigned to either: (1) moclobemide arm (n = 67) Duration: 8 weeks Treatment Protocol: fixed‐flexible dosage, range = 300 ‐ 600 mg, M and SD not provided (2) clomipramine arm (n = 68) Duration: 8 weeks Treatment Protocol: fixed‐flexible dosage, range = 100 ‐ 200 mg, M and SD not provided
Outcomes	Time points for assessment: week 1, 2, 4, and 8 Outcomes: 1. number of panic attacks 2. Patients' Clinical Global Impression of Change (P‐CGI‐C) 3. Investigators' rating of Clinical Global Impression of the Severity of the patients' panic disorder (I‐CGI‐S) 4. Patients' rating of Clinical Global Impression of Severity (P‐CGI‐S) 6. Sheehan Disability Scale (SDS) 7. Hamilton Rating Scale for Anxiety (HAMA) 8. Montgomery–Åsberg Depression Rating Scale (MADRS)
Notes	Date of study: Not stated Funding source: Hoffmann ‐ La Roche Declarations of interest among the primary researchers: Not stated.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized".
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double‐blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double‐blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "it was estimated that the ITT population with two‐sided significance level of 0.05 and a power of at least 0.8 had to be at least 66 patients in each treatment group"; "the ITT population comprised 135 patients who had received treatment and at least one assessment after baseline".
Selective reporting (reporting bias)	Unclear risk	All outcomes were reported.
Other bias	High risk	Sponsored by Hoffmann‐La Roche; the role of the funder in planning, conducting and writing the study is not discussed.